Which rare Ebola strain is Merck targeting?

The report did not specify the strain, but it is described as rare and posing a global health challenge due to limited treatments.

Has molnupiravir been approved for Ebola?

No, it has not been approved; discussions with health authorities are still in early stages.

How will this affect Merck's stock (MRK)?

Potential expansion of the drug's use could boost revenues, but the impact on the stock is uncertain at this point.

Merck Explores Using COVID Pill for Rare Ebola Strain

Merck & Co. (MRK) is exploring the use of its COVID-19 antiviral pill, molnupiravir, as a treatment option for a rare Ebola strain, according to a Reuters report.

June 9, 2026

1 min read

Source: Insider Monkey

Reuters reported on June 1 that Merck & Co., Inc. (NYSE:MRK) is holding discussions with global health authorities about making its COVID-19 antiviral pill, molnupiravir, available as a treatment option for a rare strain of Ebola. The move comes amid growing concern over limited treatment options for emerging viral strains.

Details

According to the report, Merck aims to leverage molnupiravir's broad antiviral activity to address the rare Ebola strain. No further details on timeline or regulatory steps were disclosed.

Context

This initiative follows Merck's ongoing development of antiviral therapies; molnupiravir was previously authorized for COVID-19. The rare Ebola strain has raised global health concerns due to few available treatments.

What It Means for Investors

This development represents a potential expansion of molnupiravir's use, which could boost Merck's future revenues. However, discussions are still early, and no outcome is guaranteed.

Frequently Asked Questions

Molnupiravir is an antiviral drug developed by Merck, authorized for COVID-19 treatment, and now being explored for a rare Ebola strain.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.